These congruent results conclusively demonstrate that NNMT is a key component of the GC-CEBP axis during the early stages of adipogenesis and could be a potential therapeutic target for both early-onset obesity and glucocorticoid-induced obesity. The gene discussed is NNMT; the disease is obesity due to melanocortin 4 receptor deficiency.